Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,414 across all filing types
Latest filing 2024-12-17 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'Press Release' and announces positive Phase 2b clinical trial results for a drug candidate ('duvakitug') in the treatment of Inflammatory Bowel Disease (IBD). It details primary endpoint met statistics, quotes executives from Sanofi and Teva, and discusses future plans (initiating Phase 3 development). This content structure—announcing key results immediately, followed by context and forward-looking statements—is characteristic of an Earnings Release (ER) or a major corporate/pipeline update. Since it is a press release announcing specific financial/clinical performance highlights rather than a full, comprehensive report (like a 10-K or IR), 'ER' (Earnings Release) is the most appropriate classification, as it serves as the initial public announcement of performance milestones, even if the performance is clinical rather than purely financial revenue/profit.
2024-12-17 English
Communiqué de presse : Mise en ligne du document « Q4 2024 Aide-mémoire »
Report Publication Announcement Classification · 99% confidence The document is a press release ("Communiqué de presse") announcing the online posting of a document titled "Q4 2024 Aide-mémoire" (Q4 2024 Memo/Fact Sheet). It explicitly states that the full Q4 2024 results will be announced later (January 30, 2025). The purpose of the posted document is to assist financial modeling by providing a reminder of non-recurring items, exclusivity losses, currency effects, and share count. This structure—announcing the availability of supplementary data/guidance material ahead of the main earnings release—fits the description of a Report Publication Announcement (RPA), which signals the release of supporting documentation. It is not the full Earnings Release (ER) itself, nor is it the comprehensive Interim Report (IR) or Annual Report (10-K). The document's primary function is to announce the publication of another document.
2024-12-17 French
Press Release: Availability of the Q4 2024 Aide-mémoire
Report Publication Announcement Classification · 98% confidence The document is explicitly titled "Press Release" and announces the "Availability of the Q4 2024 Aide-mémoire." It states that the Q4 2024 results will be published later (January 30, 2025). The Aide-mémoire itself is described as a document to assist in financial modelling, not the comprehensive financial report (like an IR or 10-K). Since this document is an announcement about the publication/availability of another report (the Aide-mémoire), and it is a general press release format, it fits best under Report Publication Announcement (RPA) or potentially Regulatory Filings (RNS) if RPA wasn't available. Given the definition for RPA: "Announcement regarding the timing, release, or publication of company reports (often stating the report is attached or available on the website)", RPA is the most precise fit.
2024-12-17 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC under the Securities Exchange Act of 1934. It includes references to press releases attached as exhibits, but does not contain detailed financial statements or substantive financial data itself. The document length is short (1697 characters), and it primarily serves as a notification of filings and press releases rather than a full report. According to the classification rules, such filings that are announcements or reports of other documents without substantive financial data should be classified as Regulatory Filings (RNS).
2024-12-13 English
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'Press Release' and announces a significant regulatory event: the FDA granting Breakthrough Therapy designation to the drug tolebrutinib for nrSPMS. It contains key clinical trial results (HERCULES study), quotes from management, safety data, and forward-looking statements typical of a corporate announcement regarding drug development progress. This format strongly indicates an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, time-sensitive announcement about a major regulatory milestone (Breakthrough Therapy designation) rather than routine financial results (ER) or a general filing (RNS), it fits best as a specific type of corporate news release. However, among the provided codes, 'ER' (Earnings Release) is often used broadly for major periodic announcements, but this is specifically about regulatory/clinical progress. Given the content focuses on clinical trial outcomes and regulatory interaction, and it is structured as a press release, it is most closely aligned with an 'Earnings Release' (ER) if we consider it a major periodic update, or 'RNS' as a general regulatory announcement. Since it is not a full financial report (10-K, IR) or a presentation (IP), and it is a direct announcement of a positive development, 'ER' is a plausible fit for a major corporate update, but 'RNS' (Regulatory Filings/General Announcement) is the safest fit for non-financial, non-meeting specific regulatory news. Given the context of drug development news, which often falls under general regulatory announcements, I will classify it as RNS, as it is not a standard earnings report.
2024-12-13 English
Communiqué de presse : Le tolebrutinib obtient la désignation de « Médicament innovant » de la FDA pour le traitement de la sclérose en plaques secondairement progressive sans poussées
Regulatory Filings Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and announces a regulatory milestone: the FDA granting 'Breakthrough Therapy' designation to the drug tolebrutinib for treating progressive multiple sclerosis (MS). It contains clinical trial results (HERCULES study), safety data, future regulatory submission plans, and standard boilerplate information about the company (Sanofi), the disease, and forward-looking statements. This format is characteristic of an initial announcement of significant corporate or clinical news, often released to the public and investors simultaneously. It is not a comprehensive annual report (10-K), a detailed interim report (IR), a transcript (CT), or a formal regulatory filing like a proxy statement. It is best classified as an Earnings Release (ER) if it were tied to financial results, but since it is a specific, non-financial regulatory/clinical update, the most appropriate category among the choices for a general, timely announcement of significant corporate news that isn't a formal report or a specific transaction notice is the general announcement category, or potentially an Investor Presentation (IP) if it were structured as slides, but here it reads like a news release. Given the options, and recognizing this is a press release announcing a major regulatory event and trial data summary, it most closely aligns with the function of an Earnings Release (ER) in terms of being a primary, timely announcement of key developments, even if the content is clinical rather than purely financial results. However, since it is a press release announcing a regulatory event and clinical data, and not explicitly an 'Earnings Release' (ER) which usually covers financial periods, the fallback category 'Regulatory Filings' (RNS) is often used for press releases detailing regulatory achievements or clinical trial updates that don't fit other specific categories like DIV, CAP, or MANG. Given the strong focus on regulatory action (FDA designation) and clinical data summary, RNS (Regulatory Filings/Announcements) is the most suitable general classification for this type of corporate communication that isn't a formal statutory report.
2024-12-13 French

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.